InsidersTradesSigma
申报总数
公司
▲ 买入（4 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
4
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Romano Kelly A, 董事. Director active across 3 companies, notably Dorman Products, Inc.. In total, 20 filings have been published. Split: 4 buys · 0 sell. Total volume traded: €282k. History available since 13 May 2021. The latest transaction was disclosed on 30 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Romano Kelly A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
4,364 股0UGI Common StockSEC:0001722055-26-000002:0
1,070 股0Common StockSEC:0001628280-25-029319:0
46 股@ US$132.0323.6% 占其流量Common StockSEC:0001628280-25-026762:0
5,695 股0UGI Common StockSEC:0001415889-25-002992:0
15,000 股@ US$2.258111.2% 占其流量Common StockSEC:0001415889-24-018177:0
标准退出：2024年9月19日 (T+90)
27,400 股@ US$2.415321.9% 占其流量Common StockSEC:0001415889-24-018177:1
标准退出：2024年9月22日 (T+90)
1,471 股0Common StockSEC:0001628280-24-026499:0
47 股@ US$91.3317.2% 占其流量Common StockSEC:0001628280-24-024467:0
4,470 股0UGI Common StockSEC:0000884614-24-000026:0
1,510 股0Common StockSEC:0001209191-23-033611:0
38 股@ US$86.5413.3% 占其流量Common StockSEC:0001209191-23-031348:0
2,600 股0UGI Common StockSEC:0000884614-23-000015:0
30,000 股@ US$3.2933.3% 占其流量Common StockSEC:0001209191-22-060128:0
标准退出：2023年3月2日 (T+90)
1,223 股0Common StockSEC:0001209191-22-033437:0
33 股@ US$98.060.0001% mcap28.7% 占其流量Common StockSEC:0001209191-22-032399:0
8,000 股@ US$13.11100.0% 占其流量Common StockSEC:0001209191-22-022001:0
标准退出：2022年6月29日 (T+90)
2,300 股0UGI Common StockSEC:0001209191-22-007219:0
6,050 股0UGI Common StockSEC:0001209191-22-005962:0
1,064 股0Common StockSEC:0001209191-21-037508:0
44 股@ US$103.0319.5% 占其流量Common StockSEC:0001209191-21-033031:0
20 条申报中的 20 条
About Romano Kelly A
Romano Kelly A is Administrateur and has made 20 filings in total. Across the 20 recent filings available to us, they span from 2021-05-17 to 2026-02-03, with 281766 EUR in purchases and 0 EUR in sales, and the transaction nature is listed as Attribution. The filings relate to Athira Pharma, Inc., Dorman Products, Inc. and UGI CORP, with top reported amounts of 94722.37170584897 EUR, 93746.24763923424 EUR, 61661.16191963781 EUR, 31636.65736745044 EUR, 5426.200481476842 EUR and 3949.752980023398 EUR.
